Contrastingly, the previous studies only considered NASH patients, assessed only pharmacological interventions,[72] or considered surrogate outcomes (e.g., liver fatty content by ultrasound, ALT, AST, insulin sensitivity).[9, 79, 80, 81]The number of RCTs or patients included in our study was larger than the previous published report,[72] that is, 44 and 3802 versus 9 and 964, respectively. The gene discussed is INS; the disease is metabolic dysfunction-associated steatohepatitis.